Findings from the FinnGen study encompassing 120,000 women indicate that inherited breast cancer risk should be assessed in an increasingly comprehensive manner. Currently, only individual gene mutations are taken into consideration in breast cancer therapy and prevention. The study demonstrates that more extensive genomic data can be used to identify women who are at high risk of breast cancer with considerably greater accuracy. Such knowledge can especially improve risk assessment among the close relatives of breast cancer patients.
We are excited to announce that the FinnGen data freeze 4 results and summary statistics are now publicly available!
We are looking for an experienced epidemiologist to have a key role in the expansion of one of the largest research projects in Finland, FinnGen.
We are happy to announce that Novartis has joined the FinnGen research consortium. Warm welcome!
The extensive source of genetic association results based on 135.000 individuals became available this week for the whole research community.
An international research collaboration led by researchers from the University of Helsinki and Stanford University has identified rare changes in a gene called ANGPTL7 that lower intraocular pressure and significantly reduce the risk of glaucoma. The results open important new therapeutic possibilities.
Insights into how to better understand and treat COVID-19 are desperately needed. Given the importance and urgency in obtaining these insights, it is critical for the scientific community to come together around this shared purpose.
A new Finnish study demonstrated the benefits of large-scale genomic information in estimating the risk of onset for cardiac diseases, diabetes and common cancers. The findings, based on the FinnGen research dataset encompassing more than 135,000 Finns, show that new tools based on genomic data are helpful in identifying high-risk individuals not identified by the current system.
FinnGen, a large-scale academic – industry, genome research collaboration in Finland now includes eleven industry partners with the addition of the Janssen Pharmaceutical Companies of Johnson & Johnson and Maze Therapeutics.